What is the value of hemoglobin as a prognostic and predictive factor in cancer?

European Journal of Cancer, Supplement

Volumn 2, Issue 2, 2004, Pages 11-19

  Van Belle, S J P ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Anemia; Cancer; Hemoglobin; Predictive; Prognostic

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; HEMOGLOBIN; IRINOTECAN; MITOMYCIN; PACLITAXEL; PLATINUM DERIVATIVE; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; VINBLASTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; BONE MARROW DISEASE; CANCER CHEMOTHERAPY; CANCER MODEL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONFERENCE PAPER; DISEASE ASSOCIATION; FATIGUE; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; KIDNEY CANCER; LEUKEMIA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DOCUMENTATION; NONHODGKIN LYMPHOMA; NONHUMAN; OUTCOMES RESEARCH; OVARY CANCER; PARAMETER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN FUNCTION; QUALITY OF LIFE; RETROSPECTIVE STUDY; SOLID TUMOR; UTERINE CERVIX CANCER;

EID: 2442586799     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(03)00103-4     Document Type: Conference Paper

References (43)

1. Mercadante S., Gebbia V., Marrazzo A., Filosto S. Anaemia in cancer pathophysiology and treatment. Cancer Treat. Rev. 26:2000;303-311
2. Bron D., Meuleman N., Mascaux C. Biological basis of anemia. Semin. Oncol. 28:(Suppl. 8):2001;1-6
3. Littlewood T.J. Erythropoietin for the treatment of anemia associated with hematological malignancy. Hematol. Oncol. 19:2001;19-30
4. Ludwig H. Epoetin in cancer-related anaemia. Nephrol. Dial. Transplant. 14:(Suppl. 2):1999;85-92
5. Caro J.J., Salas M., Ward A., Goss G. Anemia as an independent prognostic factor for survival in patients with cancer a systemic, quantitative review. Cancer. 91:2001;2214-2221
6. Höckel M., Schlenger K., Aral B., Mitze M., Schäffer U., Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56:1996;4509-4515
7. Sutherland R.M. Tumor hypoxia and gene expression - implications for malignant progression and therapy. Acta Oncol. 37:1998;567-574
8. Vaupel P., Kelleher D.K., Höckel M. Oxygen status of malignant tumors pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol. 28:(Suppl. 8):2001;29-35
9. Höckel M., Vaupel P. Tumor hypoxia definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 93:2001;266-276
10. Moullet I., Salles G., Ketterer N., et al. Frequency and significance of anemia in non-Hodgkin's lymphoma patients. Ann. Oncol. 9:1998;1109-1115
11. Federico M., Vitolo U., Zinzani P.L., et al. Prognosis of follicular lymphoma a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linformi. Blood. 95:2000;783-789
12. Callea V., Clo V., Morabito F., et al. Retrospective analysis of mantle cell lymphoma experience of the "Gruppo Italiano per lo Studio dei Linfomi" (GISL). Haematologica. 83:1998;993-997
13. Samaha H., Dumontet C., Ketterer N., et al. Mantle cell lymphoma a retrospective study of 121 cases. Leukemia. 12:1998;1281-1287
14. Hasenclever D, Diehl V, for the International Prognostic Factors Project on Advanced Hodgkin's Disease. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998, 339, 1506-1514.
15. Liao Z., Ha C.S., Fuller L.M., et al. Subdiaphragmatic stage I & II Hodgkin's disease long-term follow-up and prognostic factors. Int. J. Radiat. Oncol. Phys. 41:1998;1047-1056
16. Landman-Parker J., Pacquement H., Leblanc T., et al. Localized childhood Hodgkin's disease response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy - results of the French Society of Pediatric Oncology Study MDH90. J. Clin. Oncol. 18:2000;1500-1507
17. Kern W., Schoch C., Haferlach T., et al. Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy relevance of cytogenetic abnormalities. Leukemia. 14:2000;226-231
18. Albain K.S., Crowley J.J., LeBlanc M., Livingston R.B. Survival determinants in extensive-stage non-small-cell lung cancer the Southwest Oncology Group experience. J. Clin. Oncol. 9:1991;1618-1626
19. Ylisirnio S., Sassi M.L., Risteli J., Turpeenniemi-Hujanen T., Jukkola A. Serum type I collagen degradation markers, ICTP and CrossLaps, are factors for poor survival in lung cancer. Anticancer Res. 19:1999;5577-5581
20. Wilhelm R., Kovacs G., Heinrichsohn D., Galalae R., Kimmig B. Survival of exclusively irradiated patients with NSCLC. Significance of pretherapeutic hemoglobin level. Strahlenther. Onkol. 174:1998;128-132
21. Ohlhauser C., Bulzebruck H., Ebert W., Drings P., Wannenmacher M. Prognostic factors for survival in inoperable non-small-cell lung cancer a multivariate regression analysis of 456 patients with radiatiotherapy. Onkologie. 20:1997;126-131
22. Obermair A., Petru E., Windbichler G., et al. Significance of pretreatment serum hemoglobin and survival in epithelial ovarian cancer. Oncol. Rep. 7:2000;639-644
23. Eisenhauer E.A., Vermorken J.B., van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer a multivariate analysis of 704 patients. Ann. Oncol. 8:1997;963-968
24. Grogan M., Thomas G.M., Melamed I., et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer. 86:1999;1528-1536
25. Thomas G. The effect of hemoglobin level on radiotherapy outcomes the Canadian experience. Semin. Oncol. 28:(Suppl. 8):2001;60-65
26. Obermair A., Cheuk R., Horwood K., et al. Impact of hemoglobin levels before and during concurrent chemoradiotherapy on the response of treatment in patients with cervical carcinoma preliminary results. Cancer. 92:2001;903-908
27. Motzer R.J., Mazumdar M., Bacik J., Berg W., Amsterdam A., Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17:1999;2530-2540
28. Masuda H., Kurita Y., Fukuta K., et al. Significant prognostic factors for 5-year survival after curative resection of renal cell carcinoma. Int. J. Urol. 5:1998;418-422
29. Kumar P. Impact of anemia in patients with head and neck cancer. Oncologist. 5:(Suppl. 2):2000;13-18
30. Vaupel P., Thews O., Hoeckel M. Treatment resistance of solid tumors. Med. Oncol. 18:2001;243-259
31. Harrison L.B., Chadha M., Hill R.J., Hu K., Shasha D. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist. 7:2002;492-508
32. Wagner W., Hermann R., Hartlapp J., et al. Prognostic value of hemoglobin concentrations in patients with advanced head and neck cancer treated with combined radio-chemotherapy and surgery. Strahlenther. Onkol. 176:2000;73-80
33. Glaser C.M., Millesi W., Kornek G.V., et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int. J. Radiat. Oncol. Biol. Phys. 50:2001;705-715
34. Vollmer R.T., Kantoff P.W., Dawson N.A., Vogelzang N.J. A prognostic score for hormone- refractory prostate cancer analysis of two cancer and leukemia group b studies. Clin. Cancer Res. 5:1999;831-837
35. Pangalis G.A., Siakantaris M.P., Angelopoulou M.K., et al. Downstaging Rai stage III B-chronic lymphocytic leukemia patients with the administration of recombinant human erythropietin. Haematologica. 87:2002;500-506
36. Beguin Y. Erythropoiesis and erythropoietin in multiple myeloma. Leuk. Lymphoma. 18:1995;413-421
37. Dammacco F., Castoldi G., Rodjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br. J. Haematol. 113:2001;172-179
38. Cheson B.D. Chronic lymphoid leukemias and plasma cell disorders. Dale D.C., Federmann D.D. American Scientific Medicine, Vol. 12(XV). 1999;1-10 WebMD Corp, New York, NY
39. San Miguel J.F., Blade Creixenti J., Garcia-Sanz R. Treatment of multiple myeloma. Haematologica. 84:1999;36-58
40. Teicher B.A., Dupuis N.P., Emi Y., Kakeji Y., Menon K. Increased efficacy of chemo- and radio-therapy by a hemoglobin solution in the 9L gliosarcoma. In Vivo. 9:1995;11-18
41. Teicher B.A., Ara G., Herbst R., Takeuchi H., Keyes S., Northey D. PEG-hemoglobin effects on tumor oxygenation and response to chemotherapy. In Vivo. 11:1997;301-311
42. Silver D.F., Piver M.S. Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer a possible oxygen effect. Gynecol. Oncol. 73:1999;280-284
43. Littlewood T.J., Bajetta E., Nortier J.W., Vercammen E., Rapoport B. Effects of epoetin alpha on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy results of a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 19:2001;2865-2874